- Bupa Platinum consultant
- Fee assured
- Verified account
- Open Referral network
- Video and telephone consultations
Prof Nicholas Turner
Consultant Medical Oncologist MA FRCP PhD
Prof Nicholas Turner is a Consultant Medical Oncologist who specialises in the treatment of breast cancer. Prof Turner read Natural Sciences at Cambridge University before qualifying in 1997 from the University of Oxford Medical School. After completing general medical training in London, he trained in medical oncology at Royal Free and University College Hospitals and completed a PhD at The Institute of Cancer Research in 2006. He joined the Breast Unit of The Royal Marsden as a Consultant in Medical Oncology in 2008. He was elected a fellow of the Academy of Medical Sciences in 2021.
He is Head of the Ralph Lauren Centre for Breast Cancer Research and Group Leader in Molecular Oncology at the Breast Cancer Now Research Centre at the Institute of Cancer Research (ICR). He is the Precision Diagnostics and Cancer Evolution Theme Lead for The Royal Marsden and ICR NIHR Biomedical Research Centre. He has been awarded multiple prizes for his research including the AACR Outstanding Investigator Award for Breast Cancer Research in 2017, the AACR Team Science Award in 2022, the Pezcoller Foundation – EACR Translational Cancer Researcher Award in 2022, and the ESMO award for Translational Research in 2023.
Professor Turner is the Breast Domain Lead of the Genomics England Clinical Interpretation Partnerships, and has co-chaired the ASCO/CAP and chaired the ESMO review committees on circulating tumor DNA analysis in patients with cancer. He sits on the organising committees of many international conferences on breast cancer, was the executive chair of the IMPAKT 2015 breast cancer conference, and is a scientific editor of the journal Cancer Discovery. He is Chief Investigator of a number of national and international trials of precision therapy in breast cancer. His research interests include the development of new therapies for breast cancer and using liquid biopsies to deliver more precise treatment for breast cancer.
Areas of interest
Medical treatment of breast cancer;
Adjuvant and neo-adjuvant treatment of early breast cancer;
Treatment of advanced and metastatic breast cancer;
New therapies for breast cancer;
Reference number 4431864
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.
Information for healthcare professionals (Bupa patients only, last 12 months)
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-21 days - (5-50)
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-28 days - (5-50)
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-14 days - (5-50)